ArticleMolecular biology reports2025
Aqueous and ethanolic extracts of Moringa oleifera leaves induce selective cytotoxicity in Raji and Jurkat cell lines by activating the P21 pathway independent of P53.
Article in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed.
- Immunotherapy in acute myeloid leukemia: The antibodies, TriKEs, and CARs on the arduous road to cure.Blood reviews · 2026Review
- A dual-mechanism model of Selinexor in DLBCL: p53 reactivation and metabolic reprogramming.Journal of translational medicine · 2026Article
- Astrocytic SIRT3 Alleviates Neuroinflammatory Responses After Cerebral Ischemia/reperfusion by Inhibiting the cGAS-STING Pathway.Inflammation · 2026Article
- Intratumoral Collinsella aerofaciens exhibits antitumor activity in endometrial carcinoma through activation of the p53 signaling pathway.Journal of translational medicine · 2025Article
- Beyond single biomarkers: multi-omics strategies to predict immunotherapy outcomes in blood cancers.Clinical and experimental medicine · 2025Review
- Mechanistic insights into SLAMF8-mediated prostate cancer metastasis via the TLR4-NF-κB pathway.Journal of translational medicine · 2025Article
- CAR-T and CAR-NK cell therapies in AML: breaking barriers and charting the future.Journal of translational medicine · 2025Review
- Investigation of ESR Values in the Diagnosis of Malignancies: A Cross-Sectional Study.Health science reports · 2025Article
- Construction of a feature gene and machine prediction model for inflammatory bowel disease based on multichip joint analysis.Journal of translational medicine · 2025Article
- TRIP13-induced NUSAP1 upregulation promotes CcRCC progression through EMT and PI3K/AKT/mTOR pathway.Journal of translational medicine · 2025Article
- CDH3 promotes the progression of lung adenocarcinoma through driving epithelial-mesenchymal transition progress.Journal of translational medicine · 2025Article
- Phosphofructokinase-1 redefined: a metabolic hub orchestrating cancer hallmarks through multi-dimensional control networks.Journal of translational medicine · 2025Review
- ImmuProgML: machine learning-based dissection of cancer-immune dynamics during tumor progression to improve immunotherapy.Journal of translational medicine · 2025Article
- Epicatechin attenuates the stemness of liver cancer stem cells and tumorigenesis through DNA methylation-mediated inactivation of GINS1/HRAS.Journal of translational medicine · 2025Article
- The AML immune paradox: decoding escape pathways and pioneering checkpoint, vaccine, and combination strategies.Clinical and experimental medicine · 2025Review
- Mechanistic study of CTHRC1 in promoting Wilms' tumor progression by regulating M2-type tumor-associated macrophages polarization.Journal of translational medicine · 2025Article
- The type I collagen paradox in PDAC progression: microenvironmental protector turned tumor accomplice.Journal of translational medicine · 2025Review
- The epigenetic revolution in hematology: from benchside breakthroughs to clinical transformations.Clinical and experimental medicine · 2025Review
- Exploring the Functional Properties of Leaves ofAntioxidants (Basel, Switzerland) · 2025Article
- Targeting acute myeloid leukemia through antibody engineering: innovations in immunotherapy and combination regimens.Clinical and experimental medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe traditional use of Moringa oleifera (MO), an essential food source in Africa and Asia, to cure various diseases dates back thousands of years. This study examines the aqueous and ethanolic leaf extracts of MO's in vitro anti-leukemia capabilities.
methodsAfter preparing aqueous and ethanolic MO leaf extracts, cells were treated with various concentrations for 48 h. Cell viability was measured via MTT assay, and apoptotic pathways were analyzed using flow cytometry and Annexin V-PI staining. Following RNA extraction and cDNA synthesis, cells were exposed to the IC50 (150 µg/ml) for 48 h. Real-time PCR assessed the expression of P21, P53, BCL2, and Survivin genes. Peripheral blood mononuclear cells (PBMCs) served as the control group.
resultsMO aqueous and ethanol extracts showed cytotoxicity, with cancer cells being more sensitive. Flow cytometry confirmed higher apoptotic activity in Jurkat and Raji cells compared to PBMCs. The extracts increased P21 expression in Jurkat cells but did not significantly affect P53, BCL2, or Survivin. Similarly, in Raji cells, P21, BCL2, and Survivin were elevated, while P53 remained unchanged. Gene expression in healthy PBMCs was unaffected by the extracts.
conclusionThis study shows that leukemia cells (Raji and Jurkat) are more sensitive to MO's aqueous and ethanolic extracts than healthy cells. The results suggest developing MO extracts as a cutting-edge leukemia treatment.
Indexed as
Identifiers
39760794What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.